Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional StudyMarie Selvy, David Balayssac, Martin Soubrier et al.|Frontiers in Pharmacology|2021Cited by 53
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 studyMurielle Roussel, Marguerite Vignon, Valérie Lauwers‐Cancès et al.|Blood|2022Cited by 25
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencingAnaïs Schavgoulidze, Jill Corre, Aurore Perrot et al.|Blood|2025Cited by 15
Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional studyFabrice Giraudet, David Balayssac, Marie Selvy et al.|European Archives of Oto-Rhino-Laryngology|2022Cited by 7